Skip to main content
Medical information Clinical review pending

Genetic Testing

ATP7A Gene Spinal Muscular Atrophy Distal X-Linked Genetic Test

Genetic test to identify mutations in the ATP7A gene, associated with spinal muscular atrophy and other neurological disorders. Uses Next Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample (collection kit provided). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood or saliva sample. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ATP7A Gene Spinal Muscular Atrophy Distal X-Linked Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of spinal muscular atrophy (e.g., muscle weakness, atrophy)
  • ✓Family history of spinal muscular atrophy or related neurological disorders
  • ✓Diagnosis of neurological disorders of unknown origin
  • ✓Genetic counseling for individuals with potential risk factors
  • ✓Prenatal or preimplantation genetic diagnosis considerations
02

In plain language

What this test helps you understand

This test helps identify mutations in the ATP7A gene, which can confirm a diagnosis or assess risk for spinal muscular atrophy and related neurological disorders. It aids in understanding the genetic basis of a patient's condition, guiding treatment decisions, and informing family planning.
The ATP7A Gene Spinal Muscular Atrophy Distal X-Linked NGS Genetic DNA Test is a specialized genetic analysis designed to detect mutations within the ATP7A gene. This gene is linked to conditions such as spinal muscular atrophy and other neurological disorders. The test utilizes advanced Next Generation Sequencing (NGS) technology for a comprehensive examination of the genetic material, identifying potential abnormalities related to these conditions. Understanding genetic predispositions is vital for early diagnosis and effective management. This test is particularly relevant for individuals with a family history of neurological disorders, offering insights to guide treatment and care plans. The test specifically looks for mutations in the ATP7A gene by analyzing the genetic code, determining if an individual carries variations that could increase their risk for spinal muscular atrophy and related neurological issues. Results are interpreted by genetic counselors to discuss implications and guide next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood or saliva sample. However, confirm with the laboratory for any specific instructions.
SampleBlood sample (EDTA tube) or Saliva sample (collection kit provided). Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the ATP7A gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific mutations within the ATP7A gene. It may not detect all possible mutations or variations. Results should be interpreted in conjunction with clinical findings and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The ATP7A gene provides instructions for making a protein involved in transporting copper across cell membranes. Mutations in this gene can lead to neurological disorders like spinal muscular atrophy.
This test detects mutations (changes) in the ATP7A gene that are associated with spinal muscular atrophy and related neurological conditions.
Individuals experiencing symptoms like muscle weakness or atrophy, or those with a family history of spinal muscular atrophy or similar neurological disorders, may be candidates for this test.
A genetic counselor will help interpret the test results, explaining the findings and their potential implications for your health and family.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
You can book the test by calling or WhatsApping us at +254711564616. We have branches in Nairobi, Mombasa, and Kisumu, and offer home sample collection.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp